In this 46:30 audio, Danny Cohen and myself discuss why we believe $GLYC will see successful data-read outs in all studies of Uproleselan (GMI-1271). In a general sense, it makes perfect sense to be short here and predict failure. We…
Summary Glycomimetics’ Uproleselan is expected to read out data in relapsed/refractory and elderly newly diagnosed Acute Myeloid Leukemia (AML) after 6 years in pivotal studies. AML is a disease with a poor prognosis, especially for elderly patients, and there is…
Immunotherapy Explained Part 1. Danny and I break down immunotherapy in this 3 part series. In part 1, we discuss an overview of the basic biology behind immunotherapy. Video is around 1 hour long. We talk about the various approaches…
